- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07942259
35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort (HA35-CHEW)
Prospective Single-Arm Open-Label Clinical Study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Pain, Periodontal Inflammation, Gingival Recession and Pharyngeal Itch-Pain
To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mizhou Hui
- Telefonnummer: 13484005199
- E-post: mizhou.hui@alumni.utoronto.ca
Studiesteder
-
-
Shandong
-
Qingdao, Shandong, Kina
- Nakhia Impex LLC
-
Ta kontakt med:
- Xiaoxiao Jia
- Telefonnummer: 15621486915
- E-post: 15621486915@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-75 years old, male or female adult.
- Clinical findings of periodontal disease with mild gingival recession; with at least one of following: chronic gingival/tooth-root pain; pain after dental procedure (restoration, scaling, extraction, transplantation etc.); subjective pharyngeal itching or pharyngeal pain.
- Able to independently complete NRS scale self-assessment.
- Able to follow full 28-days three-times-daily chewable-tablet protocol.
- Voluntarily sign written informed-consent document.
Exclusion Criteria:
- Severe periodontal disease requiring immediate surgical intervention; active oral ulcer, oral malignant lesion.
- Pregnant or lactating women.
- Known hypersensitivity / allergy to hyaluronan / sodium hyaluronate or tablet excipients.
- Severe gastrointestinal diseases.
- Simultaneous participation in other oral-pharyngeal-related clinical trials.
- Psychiatric disorders that compromise study compliance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HA35 Chewable Tablets
|
Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Outcome Measures
Tidsramme: Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain |
Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
|
Pharyngeal Itching-Pain NRS Score
Tidsramme: Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain |
Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
|
Gingival Inflammatory Redness-Swelling NRS Score
Tidsramme: Baseline, Day-1, Day-7, Day-21, Day-28
|
Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling |
Baseline, Day-1, Day-7, Day-21, Day-28
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Estimated Gingival Regrowth Length (mm)
Tidsramme: Baseline, Day-21, Day-28
|
Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline |
Baseline, Day-21, Day-28
|
|
Exploratory Facial-tissue Reduction Score
Tidsramme: Baseline, Day-28
|
Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only |
Baseline, Day-28
|
|
Participant Overall Satisfaction Score
Tidsramme: Day-28 end-of-treatment
|
Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied |
Day-28 end-of-treatment
|
|
Adverse Event Incidence
Tidsramme: Entire 28-day study period
|
Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation |
Entire 28-day study period
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HA35202612
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .